RT Journal Article SR Electronic T1 Prostate-specific antigen: How to advise patients as the screening debate continues JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP 521 OP 527 VO 72 IS 6 A1 Peter C. Albertsen YR 2005 UL http://www.ccjm.org/content/72/6/521.abstract AB There is still no consensus on whether prostate-specific antigen (PSA) measurement should be used as a screening test for prostate cancer, but patients have the right to be informed about its risks and possible benefits. PSA testing is more likely to be beneficial in relatively young men and men at higher risk (ie, African Americans and men with a family history of prostate cancer). A possible schedule is to test at age 40, age 45, and every 2 to 3 years from age 50 until about age 75.